XILIO THERAPEUTICS, INC. XLO 深 滬
等待開盤 09-16 09:30:00 美东时间
0.7517
+0.015
+2.05%
華盛通- 最 高0.7647
- 今 開0.735
- 成交量 52.01万股
- 最 低 0.7289
- 昨 收 0.7366
- 總市值 3892.48万
- 52周最高 1.70
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.615
- 委 比 -85.70%
- 總股本 5178.23万
- 歷史最高 27.95
- 量 比 0.20
- 振 幅 4.86%
- 歷史最低 0.49
- 每 手 1
- 風險率 0.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Xilio Therapeutics Initiates Patient Dosing In Phase 2 Of An Ongoing Phase 1/2 Clinical Trial Evaluating Efarindodekin Alfa As Monotherapy In Patients With Certain Advanced Solid Tumors
Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumorsAchievement of milestone extends anticipated cash runway into first quarter of
09-09 19:37
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
Xilio Therapeutics announced the initiation of Phase 2 for efarindodekin alfa (XTX301), a tumor-activated IL-12, in patients with advanced solid tumors, following promising Phase 1 data showing two partial responses and a generally well-tolerated safety profile. The company also achieved a $17.5 million development milestone under its license agreement with Gilead Sciences, extending its cash runway into the first quarter of 2027. Efarindodekin a...
09-09 11:30
Xilio Therapeutics Q2 EPS $(0.16) Misses $(0.08) Estimate, Sales $8.084M Miss $8.210M Estimate
Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.08) by 100 percent. This is a 33.33 percent increase over losses of $(0.24) per share from
08-14 19:33
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
Catalyst Pharmaceuticals, Inc. announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran brings over 25 years of pharmaceutical experience, including strategic leadership roles at Takeda Pharmaceutical Company and as CEO of Timberlyne Therapeutics. Patrick J. McEnany, Chairman of Catalyst's Board, highlighted Dr. Curran's expertise in rare diseases and business development, which will support the company's growth strat...
08-04 12:03
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
Xilio Therapeutics announced the appointment of Dr. Akintunde (Tunde) Bello to its board of directors. With over 25 years of experience in oncology research and development, Dr. Bello has successfully developed novel therapies, including cancer immunotherapies like anti-CTLA-4, PD-1, and T-cell engagers. His expertise will support Xilio’s clinical advancements, particularly with its masked PD-1/IL-2 bi-specific, XTX501, and its T-cell engager pro...
06-10 20:30
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics granted stock options to five new employees for 181,300 shares under its 2022 Inducement Stock Incentive Plan. The options have an exercise price of $1.07 per share, equal to the closing price on May 30, 2025. They vest over four years, with 25% after the first year and the remaining 75% in 36 monthly installments. The company, focused on tumor-activated immuno-oncology therapies, aims to improve cancer outcomes with localized ...
06-03 20:30
Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gain...
06-03 00:49
Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings
U.S. stocks traded lower this morning, with the Dow Jones index falling over 30...
06-02 22:16
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Lyra Therapeutics (NASDAQ:LYRA) shares moved upwards by 463.3% to $27....
06-02 20:07
